The Biden Administration announced in September that the federal government has run out of funding to keep providing free COVID-19 vaccines and that, absent further Congressional action, it is preparing to transition vaccines to the commercial market. That move, according to a new Kaiser Family Foundation (KFF) analysis, could increase spending on COVID-19 vaccines by billions of dollars per year.
"Manufacturers will be negotiating prices directly with insurers and purchasers, not just the federal government, and prices are expected to rise," according to the Dec. 7 report, titled "How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?"
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
